@article{Irs_2015, title={PCSK9 monokloonsed antikehad düslipideemia raviks: evolokumab ja alirokumab}, url={https://ojs.utlib.ee/index.php/EA/article/view/12350}, DOI={10.15157/ea.v0i0.12350}, abstractNote={<p><span style="font-family: Calibri;"><span style="font-size: medium;">Euroopa Ravimiameti (<em>European Medicines Agency,</em></span><span style="font-size: medium;"> EMA) inimravimite komitee (</span><em><span style="font-size: medium;">Committee for Human Medicinal Products</span></em><span style="font-size: medium;">, CHMP) soovitas anda müügiloa kahele uuele sama toimemehhanismiga düslipideemiaravimile: evolokumabile (</span><em><span style="font-size: medium;">Repatha, </span></em><span style="font-size: medium;">Amgen) ja alirokumabile (</span><em><span style="font-size: medium;">Praluent, </span></em><span style="font-size: medium;">sanofi aventis).</span></span></p><p> </p><p>Eesti Arst 2015; 94(9):567–570</p><p><span style="font-family: Calibri;"><span style="font-size: medium;"><br /></span></span></p>}, journal={Eesti Arst}, author={Irs, Alar}, year={2015}, month={Oct.} }